S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)

InspireMD (NSPR) Competitors

$2.09
-0.05 (-2.34%)
(As of 04:38 PM ET)

NSPR vs. GBS, CTSO, HSAQ, APYX, SRTS, ICCM, CTCX, XAIR, DXR, and LUCD

Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include GBS (GBS), Cytosorbents (CTSO), Health Sciences Acquisitions Co. 2 (HSAQ), Apyx Medical (APYX), Sensus Healthcare (SRTS), IceCure Medical (ICCM), Carmell (CTCX), Beyond Air (XAIR), Daxor (DXR), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.

InspireMD vs.

GBS (NYSE:GBS) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.

InspireMD received 2 more outperform votes than GBS when rated by MarketBeat users.

CompanyUnderperformOutperform
GBSN/AN/A
InspireMDOutperform Votes
2
4.08%
Underperform Votes
47
95.92%

GBS has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

GBS has a net margin of 0.00% compared to GBS's net margin of -320.97%. GBS's return on equity of -55.71% beat InspireMD's return on equity.

Company Net Margins Return on Equity Return on Assets
GBSN/A -85.64% -54.42%
InspireMD -320.97%-55.71%-46.53%

2.8% of GBS shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 0.3% of GBS shares are owned by insiders. Comparatively, 21.6% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

InspireMD has a consensus target price of $4.85, suggesting a potential upside of 132.06%. Given GBS's higher possible upside, analysts clearly believe InspireMD is more favorable than GBS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GBS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
InspireMD
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, GBS had 8 more articles in the media than InspireMD. MarketBeat recorded 9 mentions for GBS and 1 mentions for InspireMD. GBS's average media sentiment score of 0.59 beat InspireMD's score of 0.42 indicating that InspireMD is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GBS
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
InspireMD
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GBS has higher earnings, but lower revenue than InspireMD. GBS is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GBS$440K94.75-$8.31M-$0.56-5.00
InspireMD$6.20M7.91-$19.92M-$1.08-1.94

Summary

InspireMD beats GBS on 10 of the 16 factors compared between the two stocks.

Get InspireMD News Delivered to You Automatically

Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NSPR vs. The Competition

MetricInspireMDSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$49.03M$3.67B$4.78B$17.23B
Dividend YieldN/A2.21%2.93%3.62%
P/E Ratio-1.9414.00222.7423.45
Price / Sales7.9157.802,474.4310.42
Price / CashN/A43.3946.9417.09
Price / Book1.144.164.554.84
Net Income-$19.92M$3.69M$103.79M$969.88M
7 Day Performance-9.91%-3.38%-4.37%-1.77%
1 Month Performance-9.52%-7.97%-5.96%-2.53%
1 Year Performance104.90%13.51%6.71%78.08%

InspireMD Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GBS
GBS
0 of 5 stars
$3.62
-3.7%
N/A-5.7%$53.90M$440,000.00-6.467Gap Up
CTSO
Cytosorbents
1.1363 of 5 stars
$0.98
+2.1%
$2.50
+155.1%
-74.9%$52.25M$31.08M-1.53198Positive News
Gap Up
HSAQ
Health Sciences Acquisitions Co. 2
0 of 5 stars
$4.89
-0.8%
N/A-76.2%$54.83MN/A0.004
APYX
Apyx Medical
3.868 of 5 stars
$1.47
+0.7%
$6.17
+319.5%
-54.0%$50.92M$52.35M-2.72252Positive News
SRTS
Sensus Healthcare
2.9762 of 5 stars
$3.45
-3.6%
$7.50
+117.4%
-37.7%$56.55M$24.41M115.0435News Coverage
Positive News
ICCM
IceCure Medical
1.5551 of 5 stars
$1.25
flat
$2.95
+136.0%
-4.0%$57.03M$3.23M-3.7965Analyst Report
CTCX
Carmell
0 of 5 stars
$2.47
-8.2%
N/AN/A$47.52MN/A0.0014Gap Down
XAIR
Beyond Air
3.4643 of 5 stars
$1.67
+3.7%
$11.25
+573.7%
-80.7%$60.19MN/A-0.7898
DXR
Daxor
0 of 5 stars
$9.74
+2.1%
N/AN/A$46.17MN/A0.00N/AGap Up
LUCD
Lucid Diagnostics
1.8941 of 5 stars
$0.92
+2.2%
$2.75
+198.4%
-45.6%$44.46M$2.43M-0.7370Negative News

Related Companies and Tools

This page (NYSE:NSPR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners